ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 20 for:    S-equol
Previous Study | Return to List | Next Study

S-equol in Women With Triple Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02352025
Recruitment Status : Recruiting
First Posted : January 30, 2015
Last Update Posted : September 5, 2018
Sponsor:
Information provided by (Responsible Party):
Kate Lathrop, The University of Texas Health Science Center at San Antonio

Brief Summary:
The primary objective of this study is to determine if S-equol, an ER-beta agonist, is effective in decreasing the proliferation rate of triple negative breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: S-equol Early Phase 1

Detailed Description:
After a baseline breast tumor core biopsy, eligible women with triple negative breast cancer (ER- alpha, PR and HER-2 receptor negative) will be treated with S-equol at a dose of 50 mg twice daily for a period of about 14 days (10-21 day range). After completion of treatment, a second breast tumor sample will be obtained to compare molecular changes between the two specimens. The second pathology specimen may be from the surgical resection of the breast tumor, or a repeat core needle biopsy, if no further surgery is planned. The primary endpoint will be the absolute change in the Ki67, which is a validated marker of tumor proliferation in breast cancer. Secondary endpoints will include assessment of total ER-beta and pY36 levels as measured by immunohistochemical staining and their correlation with S-equol effects. Further treatment after surgical resection or second core needle biopsy of the tumor will be guided by tumor size, nodal status and other standard parameters, and is at the discretion of the treating physician. The Investigator hypothesizes that S-equol will cause a measurable decrease in Ki-67 in estrogen receptor beta expressing triple negative breast cancers, indicating its potential efficacy in this tumor type.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pre-surgical Clinical Trial of Therapy With S-equol in Women With Triple Negative Breast Cancer.
Actual Study Start Date : April 15, 2015
Estimated Primary Completion Date : January 31, 2019
Estimated Study Completion Date : July 31, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: S-equol
After having a core needle biopsy of the breast confirming triple negative breast cancer, eligible women enrolled on the study will be treated with S-equol at a dose of 50 mg PO twice daily for 14 days.
Drug: S-equol
S-equol should be administered orally, twice daily (12 hours apart), preferably on an empty stomach with a glass of water. Tablets should be swallowed whole.
Other Name: Equol




Primary Outcome Measures :
  1. Proliferation Rate of Triple Negative Breast Cancer [ Time Frame: 14 Days ]
    Biopsy will measured by change in Ki-67



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants must be women who are 18 years old or older.
  • Ability to consent to treatment - patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
  • Previously untreated breast cancer determined by a core needle biopsy showing invasive ductal carcinoma or invasive lobular carcinoma.
  • A prior, unrelated, breast cancer is allowed.
  • All stages of breast cancer are eligible.
  • Estrogen receptor negative - defined as less than or equal to 5% staining by IHC.
  • Progesterone receptor negative - defined as less than or equal to 5% staining by IHC.
  • HER 2 negative as defined as 2+ or less using IHC or a ratio of less than 2.0 on FISH testing.
  • Patient must be able to take oral medications. Patients may not have any impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug.
  • Patients may not be pregnant or breast feeding.
  • Patients must with eligible for surgical resection of their breast cancer or repeat biopsy after completing 14 days of treatment.
  • Patients must have a complete history and physical examination within 28 days prior to registration.
  • Patients must have a performance status of ECOG 0, 1, 2.
  • Patient may not be concurrently enrolled in another investigational drug treatment study.
  • Tissue block of initial biopsy specimen is available.

Exclusion Criteria:

  • Known hypersensitivity to S-equol or any of its excipients.
  • ECOG status 3 or 4.
  • As judged by the investigator, severe uncontrolled concurrent medical conditions, psychiatric illness or social condition that would limit compliance with study requirements.
  • Evidence of any significant clinical disorder or laboratory finding that makes it undesirable for the subject to participant in the clinical trial.
  • Any prior treatment for the current, newly diagnosed breast cancer.
  • Current use of SERMS or aromatase inhibitors.
  • Inflammatory breast cancer or patients with rapidly progressing metastatic breast cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02352025


Contacts
Contact: Epp Goodwin 210-450-5798 CTRCReferral@uthscsa.edu

Locations
United States, Texas
CTRC (Cancer Therapy and Research Center) at UTHSCSA Recruiting
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
The University of Texas Health Science Center at San Antonio
Investigators
Principal Investigator: Kate Lathrop, MD Principle Investigator

Responsible Party: Kate Lathrop, Principal Investigator, The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier: NCT02352025     History of Changes
Other Study ID Numbers: CTMS 14-2018
HSC20150231H ( Other Identifier: University of Texas Health Science Center- San Antonio )
First Posted: January 30, 2015    Key Record Dates
Last Update Posted: September 5, 2018
Last Verified: August 2018

Keywords provided by Kate Lathrop, The University of Texas Health Science Center at San Antonio:
S-equol
breast cancer
triple negative

Additional relevant MeSH terms:
Equol
Breast Neoplasms
Triple Negative Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Phytoestrogens
Estrogens, Non-Steroidal
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs